DK0901470T3 - Indolderivater egnede som endothelinreceptorantagonister - Google Patents

Indolderivater egnede som endothelinreceptorantagonister

Info

Publication number
DK0901470T3
DK0901470T3 DK97920690T DK97920690T DK0901470T3 DK 0901470 T3 DK0901470 T3 DK 0901470T3 DK 97920690 T DK97920690 T DK 97920690T DK 97920690 T DK97920690 T DK 97920690T DK 0901470 T3 DK0901470 T3 DK 0901470T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
indole derivatives
endothelin receptor
derivatives suitable
endothelin
Prior art date
Application number
DK97920690T
Other languages
Danish (da)
English (en)
Inventor
David James Rawson
Kevin Neil Dack
Roger Peter Dickinson
Kim James
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0901470T3 publication Critical patent/DK0901470T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DK97920690T 1996-05-09 1997-04-11 Indolderivater egnede som endothelinreceptorantagonister DK0901470T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9609641.7A GB9609641D0 (en) 1996-05-09 1996-05-09 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
DK0901470T3 true DK0901470T3 (da) 2004-07-12

Family

ID=10793387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97920690T DK0901470T3 (da) 1996-05-09 1997-04-11 Indolderivater egnede som endothelinreceptorantagonister

Country Status (42)

Country Link
US (4) US6017945A (de)
EP (1) EP0901470B1 (de)
JP (1) JP3245179B2 (de)
KR (1) KR100331217B1 (de)
CN (1) CN1124262C (de)
AP (1) AP830A (de)
AR (1) AR007030A1 (de)
AT (1) ATE263151T1 (de)
AU (1) AU717849B2 (de)
BG (1) BG102873A (de)
BR (1) BR9709072A (de)
CA (1) CA2253876A1 (de)
CO (1) CO4650036A1 (de)
CZ (1) CZ292928B6 (de)
DE (1) DE69728392T2 (de)
DK (1) DK0901470T3 (de)
DZ (1) DZ2227A1 (de)
EA (1) EA001471B1 (de)
ES (1) ES2218675T3 (de)
GB (1) GB9609641D0 (de)
HN (1) HN1997000058A (de)
HR (1) HRP970249B1 (de)
HU (1) HUP9901245A3 (de)
ID (1) ID16878A (de)
IL (1) IL125903A0 (de)
IS (1) IS1856B (de)
MA (1) MA26428A1 (de)
NO (1) NO312547B1 (de)
NZ (1) NZ332640A (de)
OA (1) OA10896A (de)
PE (1) PE65098A1 (de)
PL (1) PL329725A1 (de)
PT (1) PT901470E (de)
SI (1) SI0901470T1 (de)
SK (1) SK150398A3 (de)
TN (1) TNSN97078A1 (de)
TR (1) TR199802269T2 (de)
TW (1) TW491838B (de)
UA (1) UA50767C2 (de)
UY (1) UY24546A1 (de)
WO (1) WO1997043260A1 (de)
ZA (1) ZA973963B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722287D0 (en) * 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
GB0016162D0 (en) * 2000-06-30 2000-08-23 Cancer Res Campaign Tech Indole-3-acetic acid derivatives
US20050203166A1 (en) * 2000-06-30 2005-09-15 Cancer Research Technology Limited Indole-3-acetic acid derivatives
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
DE60221391T2 (de) 2001-06-20 2008-04-17 Wyeth Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
BR0316583A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
MXPA05006288A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados del acido 3-carbonil-1h-indol-1-ilacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
ATE430731T1 (de) 2002-12-10 2009-05-15 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
BRPI0406883A (pt) * 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
JP2005109006A (ja) * 2003-09-29 2005-04-21 Tdk Corp 高電圧貫通型コンデンサ及びマグネトロン
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
JP2008510814A (ja) 2004-08-23 2008-04-10 ワイス Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸
EP1794138A2 (de) 2004-08-23 2007-06-13 Wyeth Thiazolo-naphthylsäuren als inhibitoren von plasminogen-aktivator-inhibitor-1
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
CN101263115A (zh) 2005-08-17 2008-09-10 惠氏公司 经取代吲哚和其用途
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
CN106674065A (zh) * 2016-12-07 2017-05-17 贵州大学 一种5‑卤代‑2‑烷氧基‑4‑甲苯磺酰氯制备方法
GB201817038D0 (en) * 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
CN117263832B (zh) * 2023-08-18 2026-02-03 辽宁龙田化工科技有限公司 一种2-氯-4-甲磺酰基苯甲酸合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297887A (de) * 1962-09-14
DE1950346B2 (de) * 1968-10-08 1973-06-28 Sumitomo Chemical Co 2-indolylessigsaeureverbindungen und diese verbindungen enthaltende arzneipraeparate
US4397079A (en) * 1981-03-30 1983-08-09 International Business Machines Corp. Process for improving the yield of integrated devices including Schottky barrier diodes
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
WO1992004321A1 (en) * 1990-09-10 1992-03-19 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
EP0617001B1 (de) * 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylessigsäurederivate
GB9317096D0 (en) * 1993-08-17 1993-09-29 Pfizer Ltd Indoles

Also Published As

Publication number Publication date
DE69728392T2 (de) 2005-01-13
TR199802269T2 (xx) 2001-12-21
WO1997043260A1 (en) 1997-11-20
JP3245179B2 (ja) 2002-01-07
BG102873A (en) 1999-11-30
ID16878A (id) 1997-11-20
HK1019149A1 (en) 2000-01-14
IS4838A (is) 1998-08-28
OA10896A (en) 2001-10-11
US6306852B1 (en) 2001-10-23
EA001471B1 (ru) 2001-04-23
UA50767C2 (uk) 2002-11-15
CZ358298A3 (cs) 1999-08-11
AP9700982A0 (en) 1997-07-31
PT901470E (pt) 2004-07-30
CN1124262C (zh) 2003-10-15
US6136843A (en) 2000-10-24
US6017945A (en) 2000-01-25
DZ2227A1 (fr) 2002-12-25
CZ292928B6 (cs) 2004-01-14
BR9709072A (pt) 1999-08-03
AU717849B2 (en) 2000-04-06
AU2697897A (en) 1997-12-05
SI0901470T1 (en) 2004-08-31
DE69728392D1 (de) 2004-05-06
ES2218675T3 (es) 2004-11-16
EP0901470B1 (de) 2004-03-31
KR100331217B1 (ko) 2002-05-09
ATE263151T1 (de) 2004-04-15
HUP9901245A2 (hu) 1999-08-30
JPH11508285A (ja) 1999-07-21
SK150398A3 (en) 1999-03-12
IL125903A0 (en) 1999-04-11
ZA973963B (en) 1998-11-09
US6384070B2 (en) 2002-05-07
HUP9901245A3 (en) 2002-01-28
US20010014677A1 (en) 2001-08-16
TW491838B (en) 2002-06-21
IS1856B (is) 2003-02-21
AR007030A1 (es) 1999-10-13
KR20000010879A (ko) 2000-02-25
MA26428A1 (fr) 2004-12-20
HN1997000058A (es) 1997-06-26
NO985225D0 (no) 1998-11-09
HRP970249A2 (en) 1998-06-30
CA2253876A1 (en) 1997-11-20
PL329725A1 (en) 1999-04-12
HRP970249B1 (en) 2003-06-30
EA199800908A1 (ru) 1999-06-24
CN1216531A (zh) 1999-05-12
AP830A (en) 2000-05-03
CO4650036A1 (es) 1998-09-03
PE65098A1 (es) 1998-10-29
NZ332640A (en) 2001-03-30
EP0901470A1 (de) 1999-03-17
GB9609641D0 (en) 1996-07-10
UY24546A1 (es) 2000-09-29
NO985225L (no) 1998-11-09
NO312547B1 (no) 2002-05-27
TNSN97078A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
DK0901470T3 (da) Indolderivater egnede som endothelinreceptorantagonister
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
FI973205A7 (fi) Indolijohdannaisia 5-HT-reseptoriantagonisteina
DK0630376T3 (da) Kondenserede indolderivater som 5-HT4-receptorantagonister
DE69734833D1 (de) Vitronektin rezeptor antagonisten
ID24726A (id) Antagonis-antagonis reseptor trombin
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
NO974043D0 (no) Indolderivater som EAA-antagonister
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
ID24162A (id) Antagonis-antagonis reseptor vitronektin
EP0929218A4 (de) R2y rezeptor antagonisten
NO985970L (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
NO972612D0 (no) Pyridazoner som endotelinreseptorantagonister
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists
NO963775L (no) Indol-derivater som CCK-reseptorantagonister
SI0912556T1 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists